Stay updated on Lenvatinib Plus Pembrolizumab in Melanoma Clinical Trial
Sign up to get notified when there's something new on the Lenvatinib Plus Pembrolizumab in Melanoma Clinical Trial page.

Latest updates to the Lenvatinib Plus Pembrolizumab in Melanoma Clinical Trial page
- Check7 days agoChange DetectedThis updates the page’s revision/version label from **v3.5.2** to **v3.5.3** in the footer, indicating a minor site maintenance change rather than a change to the underlying trial information.SummaryDifference0.0%

- Check14 days agoChange DetectedAdded revision: v3.5.2. Removed revision: v3.5.0.SummaryDifference0.0%

- Check21 days agoNo Change Detected
- Check43 days agoChange Detected- Revision: v3.5.0 added. The previous Revision: v3.4.3 was removed.SummaryDifference0.0%

- Check57 days agoChange DetectedPage revision updated from v3.4.2 to v3.4.3.SummaryDifference0.0%

- Check79 days agoChange DetectedFooter revision updated from v3.4.1 to v3.4.2. No changes to study details, eligibility criteria, outcomes, or participating locations.SummaryDifference0.0%

- Check86 days agoChange DetectedRevision: v3.4.1 was added and Revision: v3.4.0 was removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

Stay in the know with updates to Lenvatinib Plus Pembrolizumab in Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Lenvatinib Plus Pembrolizumab in Melanoma Clinical Trial page.